TrialOrphanet journal of rare diseases2022

Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.

Peter Kühnen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.